ASCO GUIDELINES Bundle

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475447

Contents of this Issue

Navigation

Page 10 of 13

11 Oncotype DX MammaPrint a EndoPredict ProSigna Ki67 b IHC4 b BCI c uPA and PAI-1 d Oncotype DX MammaPrint a Ki67 b EndoPredict IHC4 b BCI c Insufficient evidence to recommend a biomarker for use No mature evidence to recommend use of any other biomarker for this patient population Node– 1–3 Node+ Postmenopausal or age >50 years >3 Node+ High quality of evidence/Strong strength of recommendation. Intermediate quality of evidence/Strong strength of recommendation. Intermediate quality of evidence/Moderate strength of recommendation. ER– Node+

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer